Cryo-Save N.V. has acquired Salveo Biotechnology SA
Cryo-Save N.V. (Cryo-Save), the largest family stem cell bank in Europe, has acquired Salveo Biotechnology SA, the cord banking activities of Salveo Holding SA (Salveo), for an undisclosed consideration.
Cryo-Save is the leading international stem cell storage brand. It offers collection, analysis, processing and cryogenic preservation of stem cells obtained from the umbilical cord and from umbilical cord blood that can be used in medical therapies later in a child’s lifetime.
Salveo Biotechnology SA is the umbilical cord blood and umbilical cord tissue cryopreservation division of Salveo Holding SA, a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine.
Salveo Holding SA is a Swiss private laboratory based in Geneva, specialized in stem cells cryopreservation, cell culture and regenerative medicine. Founded in 2011 and made up of experts in regenerative medicine, the group is also present in Italy, Spain, Portugal and Ukraine and has developed a dynamic and professional commercial network.
Salveo was selected to partner with Cryo-Save, acquiring all assets related to the distribution and commercial activities of Salveo's umbilical cord blood and umbilical cord tissue cryopreservation business. Frédéric Amar, CEO of Salveo, has also joined the board of Cryo-Save as non-Executive Director.
Oaklins' team in the Netherlands identified potential partners, initiated contact and led talks on potential cooperation with a number of parties and advised the buyer in this transaction.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more